Treatment strategies have not been well established for thrombotic microangiopathy associated with malignant hypertension.

Two posters highlighted the effects of sacubitril/valsartan (Entresto; Novartis) on key biomarkers and cardiac function in ...

Both sacubitril/valsartan (Entresto) and enalapril (Vasotec) were associated with improvement in clinical measures among children aged 1 month to younger than 18 years who had heart failure ...

Sacubitril/valsartan may be a better treatment option compared with ACEi/ARBs for patients with malignant hypertension-associated thrombotic microangiopathy. Kidney recovery is better when ...

Researchers have established that sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is not superior to enalapril in the treatment of heart failure (HF) in children who have ...

USV Pvt. Ltd. has introduced OnArni, a fixed dose combination of Sacubitril and Valsartan, for the management of Heart ...

New Delhi: Reviewing the justification for the variability of the kinetic data of the bioequivalence (BE) study report of the fixed-dose combination (FDC) cardiovascular drug Sacubitril plus Valsartan ...

Implantable cardioverter-defibrillators were no better than amiodarone for survival in chronic Chagas cardiomyopathy, though ...

USV introduces OnArni, a cost-effective heart failure medication at ₹8 per tablet, improving adherence and health outcomes.